Irlab Therapeutics Reports Financial Losses Amidst Promising Drug Development Milestones
Irlab Therapeutics AB reported a mixed quarter, with significant financial losses but promising developments in its drug pipeline, including a patent extension and positive clinical trial results.
2 minutes to read